<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984802</url>
  </required_header>
  <id_info>
    <org_study_id>CMX-2043-2a</org_study_id>
    <nct_id>NCT00984802</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy</brief_title>
  <acronym>SUPPORT-1</acronym>
  <official_title>A Prospective, Randomized, Comparative, Blinded, Placebo-Controlled, Three Different Intravenous Dose, Phase 2a Study of the Safety and Efficacy of CMX-2043 in Subjects Undergoing PCI and Peri-Operative Reperfusion Treatment (SUPPORT-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ischemix, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ischemix, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to assess the safety of CMX-2043 solution for intravenous (IV)
      injection, and to evaluate efficacy on the basis of the changes seen in the cardiac
      biomarkers and continuous electrocardiography (ECG) monitoring. Additionally, correlation of
      the levels/changes in the biomarkers and the pharmacokinetic evaluations of the drug will be
      explored.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by changes in CK-MB</measure>
    <time_frame>within 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac biomarkers</measure>
    <time_frame>within 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST segment changes</measure>
    <time_frame>within 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Stable Coronary Artery Disease</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CMX-2043</intervention_name>
    <description>Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.</description>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_label>Mid Dose</arm_group_label>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>Vehicle solution for IV administration single dose.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have stable coronary artery disease undergoing elective PCI.

          -  Female subjects not of child-bearing potential.

          -  Absence of ST segment depression &gt;1.0 mm and absence of ST elevation &gt;1.0 mm in any
             lead on the baseline 12-lead ECG.

          -  subjects with CK-MB and troponin-T levels lower than the upper limit of normal.

          -  Subjects free of acute injuries or illnesses.

        Exclusion Criteria:

          -  Subjects with unstable angina (angina at rest, worsening frequency, duration of
             angina) or other signs of unstable coronary artery disease.

          -  Subjects who had had an MI within 14 days prior to the PCI procedure.

          -  Subjects with conditions that contraindicate the PCI (e.g. coagulopathy, valvular
             disease, PVD).

          -  Subjects with history of TIA/stroke within 90 days or any intracranial bleed.

          -  Subjects with creatinine clearance â‰¥ 1.5 times the upper limit of normal.

          -  Subjects with an active history of psychiatric disorders that is likely to limit the
             validity of consent to participate in the study or limit the ability to comply with
             the protocol requirements.

          -  Subjects with a history of alcohol or drug abuse.

          -  Subjects with documented history of human immunodeficiency virus (HIV), or Hepatitis B
             (HBsAg) or Hepatitis C (HCV) virus positive.

          -  Subjects with uncorrected clinically significant abnormalities of clinical laboratory
             tests who in the investigators opinion will interfere with the study conduct.

          -  Subject with chronic diseases considered by the anesthetist unfit for surgery and/or
             who in the opinion of the investigator will increase the risk of the study or obscure
             the interpretation of results.

          -  Subjects who have participated in a clinical study within 1 month or are currently
             participating in a clinical study of an investigational agent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan S. Lader, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ischemix, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent Hospital</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madras Medical Mission</name>
      <address>
        <city>Chennai</city>
        <zip>600 037</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hinduja Hospital</name>
      <address>
        <city>Mumbai</city>
        <zip>400 016</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poona Hospital</name>
      <address>
        <city>Pune</city>
        <zip>411 030</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2009</study_first_posted>
  <last_update_submitted>June 17, 2011</last_update_submitted>
  <last_update_submitted_qc>June 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Duffy Dufresne</name_title>
    <organization>Ischemix, LLC</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

